Company Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 1978 |
| IPO Date | Sep 16, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7,500 |
| CEO | Christopher Viehbacher |
Contact Details
Address: 225 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 679 2000 |
| Website | biogen.com |
Stock Details
| Ticker Symbol | BIIB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000875045 |
| CUSIP Number | 09062X103 |
| ISIN Number | US09062X1037 |
| Employer ID | 33-0112644 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Viehbacher | President, Chief Executive Officer and Director |
| Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations and Technology |
| Susan H. Alexander Esq. | Executive Vice President and Chief Legal Officer |
| Dr. Priya Singhal M.D., M.P.H. | Executive Vice President and Head of Development |
| Robin C. Kramer | Executive Vice President and Chief Financial Officer |
| Sean Godbout | Vice President, Chief Accounting Officer and Global Corporate Controller |
| Guy Hadari | Chief Information Officer |
| Tim Power M.B.A., Ph.D. | Head of Investor Relations |
| Adam Keeney Ph.D. | Executive Vice President and Head of Corporate Development |
| Dr. Ginger Gregory Ph.D. | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 11, 2026 | 8-K | Current Report |
| Feb 9, 2026 | 144 | Filing |
| Feb 6, 2026 | 10-K | Annual Report |
| Feb 6, 2026 | 8-K | Current Report |
| Feb 5, 2026 | SCHEDULE 13G | Filing |
| Feb 2, 2026 | 144 | Filing |
| Jan 14, 2026 | 8-K | Current Report |
| Nov 13, 2025 | SCHEDULE 13G/A | Filing |
| Nov 10, 2025 | SCHEDULE 13G | Filing |
| Oct 30, 2025 | 10-Q | Quarterly Report |